View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 29, 2020updated 12 Jul 2022 11:48am

UK researchers study anti-inflammatory drug camostat for Covid-19

Researchers at Cancer Research UK and its partners have initiated a clinical trial to study camostat, used to treat inflammation of the pancreas, as a potential therapy against Covid-19.

Researchers at Cancer Research UK and its partners have initiated a clinical trial to study camostat, used to treat inflammation of the pancreas, as a potential therapy against Covid-19.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Named SPIKE1, the Phase III trial is being conducted by Cancer Research UK’s Centre for Drug Development’s (CDD) in alliance with Latus Therapeutics and the University of Edinburgh. LifeArc is funding the study.

Camostat has demonstrated an ability to prevent Covid-19 from entering human cells. The aim of SPIKE1 is to determine if the drug could help control symptoms of the infection and prevent the hospitalisation of patients.

As the drug is licensed in Japan and South Korea to treat chronic pancreatitis, it is expected to enable rapid manufacturing, if successful in treating Covid-19.

CDD and Latus Therapeutics obtained shipping of camostat from Ono Pharmaceutical, which produces the drug in Japan. Latus Therapeutics received £1m in funding from LifeArc to conduct a trial of the drug in Covid-19 patients.

LifeArc CEO Melanie Lee said: “As an independent medical charity with expertise in medical translation, LifeArc could rapidly offer the resources to evaluate proposals and financially support studies with the best chance of improving patient outcomes. We are pleased to support this vital work during the Covid-19 pandemic.”

The SPIKE1 trial will enrol Covid-19 patients who exhibit symptoms but do not require hospital care yet. Participants will receive daily doses of the drug and will be monitored each day via telephone, as well as self-report their temperature and blood oxygen levels.

The trial will primarily asses whether use of camostat early after Covid-19 symptoms begin could stop the infection from progressing, reducing the need for hospitalisation.

Latus Therapeutics founder Dr Bobojon Nazarov said: “Camostat belongs to the only class of drug that has a strong mechanistic basis for blocking entry of the virus into human cells.

“We believe this drug could be used to reduce the severity of Covid-19 infection, providing much needed time for the body’s immune system to recognise the virus and destroy it.”

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena